// App-Quantinova.ai

1131 : GRWD5769: A first-in-class inhibitor of ERAP1, generating novel cancer antigens to drive de novo anti-tumor T cell responses

Researchers

Presenter

  • Peter Joyce

Principal Investigators

  • Andrew Leishman

  • Asolina Braun

  • Mitul Patel

  • Michael Pinggera

  • Jessica Sette

  • Kate Anderton

  • Edd James

  • Valeriya Shunina

  • Anthony Purcell

  • Nicola Ternette

  • Jason Shiers

  • Martin Quibell

  • Wayne Paes

  • Tom McCarthy

Medical Centers

  • Deakin University, Melbourne, Australia

  • Sygnature Discovery, Nottingham, UK

  • University of Southampton, Southampton, UK

  • Grey Wolf Therapeutics Ltd, Oxford, UK

  • University of Oxford, Oxford, Germany

Locations

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • T-cell receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved